| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification / amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $34.8600 | 2,918.882 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2023-08-17 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification / amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $34.8600 | 54.313 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2023-08-17 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification / amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Following the vesting on 19 August 2023 of 50% of an award made on 19 August 2019 under the GlaxoSmithKline Deferred Investment Award Programme, Ms Ramakrishnan will receive a cash payment of $157,854.38 less applicable tax withholding in respect of 4,579.471 notional ADSs. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $34.4700 | 4,579.471 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2023-08-19 | |||
| f) | Place of the transaction | N/A | |||
| GSK plc | |
| (Registrant) | |
| Date: August 23, 2023 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GSK plc |
